CEO Andrew Whelan to present Corporate Growth Plan on Tuesday, May 20th
FREDERICK, Md., May 15 /PRNewswire-FirstCall/ -- BioElectronics Corp. (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti-inflammatory patch with an embedded battery operated microchip delivering weeks of continuous pulse therapy for a few cents an hour, today announced it will hold a conference call to update investors on the growth initiatives implemented by the company. Andrew Whelan, President and CEO of BioElectronics Corp. will outline the important changes made in 2007 to realign the company for growth and the successes currently being realized both domestically and internationally.
"These are very exciting times for BioElectronics Corporation. During 2007 we made many changes to the organization to realign in preparation for significant revenue growth," commented Mr. Whelan. "These changes are starting to yield dividends in the form of the introduction of many new products, a growing distributor base, and most importantly, strong revenue growth. Please join us next week as we outline the changes we have made to the organization and our exciting growth prospects for 2008 and beyond."
The conference call will be held on Tuesday, May 20, 2008 at 4:15 p.m. (EDT). To access the conference call from within the United States and Canada please dial (800) 610-4500 and enter access code 37321. To access the call from locations outside of the United States and Canada, please dial (702) 851-3339 and enter access code 37321.
About BioElectronics Corporation
BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch
is a drug-free anti-inflammatory patch with an embedded battery operated
microchip that delivers weeks of continuous pulsed therapy for about a
dollar a day. The unique ActiPatch delivery system, using patented
technology, provides a cost-effective patient friendly method to reduce
soft tissue pain and swelling. ActiPatch is approved by Health Canada for
the relief of pain in musculoskeletal complaints. The US government's Food
and Drug Administration (FDA) has cleared the use of the product for
reducing edema (swelling) following blepharoplasty and the European Union
has approved the product as a class II pulsed electromagnetic medical
device as have numerous other international regulatory agencies.
Information on ActiPatch and BioElectronics Corporation is available at the
-- U.S. Consumer http://www.actipatchonline.com
-- Podiatry: http://www.pemfpodiatry.com
-- Plastic Surgery: http://www.plasticsurgeryrelief.com and
-- German orthopedic foot & ankle: http://www.diesfussexperten.de
-- Italy and Switzerland: http://www.actipatch.it
-- Canada: http://www.actipatchpaintherapy.ca
-- Netherlands: http://www.actipatch.de
-- Singapore & Malaysia: http://www.astonixlife.com/
-- BioElectronics Corp: http://www.bioelectronicscorp.com
Safe Harbor Statement
This news release contains forward-looking statements related to future
growth and earnings opportunities. Such statements are based upon certain
assumptions and assessments made by management in light of current
conditions, expected future developments and other factors it believes to
be appropriate. Actual results may differ as a result of factors over which
the company has no control.
Patricia Baker, The Big Picture Agency LLC
Voice: 413-623-0950 ext. 221, email: email@example.com
Investor Relations Contact:
Joe Noel, Emerging Growth Research LLP
Voice: 925-922-2560, email: firstname.lastname@example.org
|SOURCE BioElectronics Corporation|
Copyright©2008 PR Newswire.
All rights reserved